Stockreport
Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
gains, 14 products topping $1B and 18 achieving record sales, driven by six growth pillars including Repatha, Tezspire, rare disease, innovative oncology (BiTE) and biosimilars. Rare disease — UPLIZNA surge: UPLIZNA sales rose 73% in 2025 after the IgG4-related disease launch and a gMG approval, and Amgen plans additional Phase III studies in autoimmune hepatitis and CIDP to expand indications. Pipeline & oncology focus: Amgen's BiTE platform is gaining traction (IMDELLTRA now a 2L+ SCLC standard with multiple Phase III studies) while MariTide advances in six global Phase III trials for obesity, emphasizing monthly/quarterly dosing to boost adherence and long-term persistence. Interested in Amgen Inc.? Here are five stocks we like better. Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference s
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- 4 Biotech Stocks to Watch for Potential Upside in 2026 [Yahoo! Finance][Yahoo! Finance]
- Two major drug companies are the latest to join TrumpRx [FOX Business Network][FOX Business Network]
- Rapid Micro Biosystems Q4 Earnings Call Highlights [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha][Seeking Alpha]
- Amgen (AMGN) is now covered by Jefferies Financial Group Inc.. They set a "hold" rating and a $350.00 price target on the stock.[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 3/6/26 - Form 4
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- AMGN's page on the SEC website
- More